Obesity is a disease with biological causes that disrupts the bodys ability to regulate weight, often leading to serious health conditions, said Dr
Dhillon, 2018), while trials of IDH inhibitors for other tumors such as cholangiocarcinoma, chondrosarcoma, and myelodysplastic syndrome are still underway (Abou-Alfa et al., 2020
The problem is that these uses are not well studied, and the risks are often not explained
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A multicentre, randomised, double-blind, placebo-controlled study
GLP-1: The trusted option with a proven track record for sustained weight loss, cardiovascular protection, and long-term health benefits